Primary Ipilimumab and Nivolumab combo-immunotherapy followed by adjuvant Nivolumab in locally advanced or limited metastatic melanoma. - NA

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2020
This article has no abstract
Epistemonikos ID: fe91fb455342c87875e28bdba2c23da98e3e2dad
First added on: Apr 17, 2025